Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,185.56
+2,919.53(+6.18%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

GlaxoSmithkline Pharmaceuticals Limited (GLAXO.BO)

BSE - BSE Real-time price. Currency in INR

Add to watchlist

2,093.85

-9.70

(-0.46%)

At close: 03:29PM IST

Currency in INR

Valuation measures⁴

Market cap (intra-day)	356.35B
Enterprise value	339.35B
Trailing P/E	67.36
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	10.76
Price/book (mrq)	23.15
Enterprise value/revenue	10.25
Enterprise value/EBITDA	42.10

Trading information

Stock price history

Beta (5Y monthly)	0.22
52-week change ³	68.43%
S&P500 52-week change ³	22.43%
52-week high ³	2,649.95
52-week low ³	1,242.00
50-day moving average ³	2,033.41
200-day moving average ³	1,763.47

Share statistics

Avg vol (3-month) ³	9.82k
Avg vol (10-day) ³	7.24k
Shares outstanding ⁵	169.41M
Implied shares outstanding ⁶	169.41M
Float ⁸	41.35M
% held by insiders ¹	75.58%
% held by institutions ¹	9.53%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	32
Forward annual dividend yield ⁴	1.52%
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	1.73
Payout ratio ⁴	102.47%
Dividend date ³	N/A
Ex-dividend date ⁴	30 Jun 2023
Last split factor ²	2:1
Last split date ³	11 Sept 2018

Financial highlights

Fiscal year

Fiscal year ends	31 Mar 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	15.97%
Operating margin (ttm)	24.95%

Management effectiveness

Return on assets (ttm)	N/A
Return on equity (ttm)	N/A

Income statement

Revenue (ttm)	33.11B
Revenue per share (ttm)	195.51
Quarterly revenue growth (yoy)	0.40%
Gross profit (ttm)	N/A
EBITDA	7.99B
Net income avi to common (ttm)	5.29B
Diluted EPS (ttm)	31.13
Quarterly earnings growth (yoy)	-72.20%

Balance sheet

Total cash (mrq)	16.05B
Total cash per share (mrq)	94.8
Total debt (mrq)	213.8M
Total debt/equity (mrq)	1.39%
Current ratio (mrq)	N/A
Book value per share (mrq)	90.88

Cash flow statement

Operating cash flow (ttm)	N/A
Levered free cash flow (ttm)	N/A